

1    WHAT IS CLAIMED IS:

2                   1.       A method of treating migraine in a subject in need thereof, the  
3   method comprising the step of administering to the subject an amount of a glucocorticoid  
4   receptor antagonist effective to treat migraine in the subject,

5                   (i)       with the proviso that the subject is not otherwise in need of  
6   treatment with a glucocorticoid receptor antagonist, and

7                   (ii)      with the proviso that the subject is not also being treated with  
8   triptans nor any other pharmaceutically prescribed entity that is predominantly  
9   metabolized by a cytochrome P450-3A4 isoenzyme.

1                   2.       The method of claim 1, wherein the subject is a human.

1                   3.       The method of claim 1, wherein the treatment for migraine is  
2   administered prophylactically.

1                   4.       The method of claim 3, wherein the treatment for migraine is  
2   administered daily.

1                   5.       The method of claim 1, wherein the treatment for migraine is  
2   administered during the course of a migraine attack.

1                   6.       The method of claim 1, wherein the glucocorticoid receptor  
2   antagonist comprises a steroidal skeleton with at least one phenyl-containing moiety in the  
3   11-beta position of the steroidal skeleton.

1                   7.       The method of claim 6, wherein the phenyl-containing moiety in the  
2   11-beta position of the steroidal skeleton is a dimethylaminophenyl moiety.

1                   8.       The method of claim 7, wherein the glucocorticoid receptor  
2   antagonist is mifepristone.

1                   9.       The method of claim 7, wherein the glucocorticoid receptor  
2   antagonist is selected from the group consisting of 11 $\beta$ -(4-dimethylaminoethoxyphenyl)-  
3   17 $\alpha$ -propynyl-17 $\beta$ -hydroxy-4,9-estradien-3-one and 17 $\beta$ -hydroxy-17 $\alpha$ -19-(4-  
4   methylphenyl)androst-4,9(11)-dien-3-one.

1                   10.     The method of claim 1, wherein the glucocorticoid receptor  
2 antagonist is selected from the group consisting of 4 $\alpha$ (S)-Benzyl-2(R)-prop-1-ynyl-  
3 1,2,3,4,4 $\alpha$ ,9,10,10 $\alpha$ (R)-octahydro-phenanthrene-2,7-diol and 4 $\alpha$ (S)-Benzyl-2(R)-  
4 chloroethynyl-1,2,3,4,4 $\alpha$ ,9,10,10 $\alpha$ (R)-octahydro-phenanthrene-2,7-diol.

1                   11.     The method of claim 1, wherein the glucocorticoid receptor  
2 antagonist is (11 $\beta$ ,17 $\beta$ )-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-  
3 dien-3-one.

1                   12.     The method of claim 1, wherein the glucocorticoid receptor  
2 antagonist is administered in a daily amount of between about .5 to about 35 mg per  
3 kilogram of body weight per day.

1                   13.     The method of claim 12, wherein the glucocorticoid receptor  
2 antagonist is administered in a daily amount of between about 5 to about 15 mg per  
3 kilogram of body weight per day.

1                   14.     The method of claim 1, wherein the administration is once per day.

1                   15.     The method of claim 1, wherein the mode of administration is by a  
2 transdermal application, by a nebulized suspension, or by an aerosol spray.

1                   16.     The method of claim 1, wherein the mode of administration is oral.

1                   17.     A kit for treating migraine in a subject,  
2 the kit comprising:  
3                   (i) a specific glucocorticoid receptor antagonist; and,  
4                   (ii) an instructional material teaching the indications, dosage and  
5 schedule of administration of the glucocorticoid receptor antagonist to a patient with the  
6 migraine.

1                   18.     The kit of claim 17, wherein the instructional material indicates that  
2 the glucocorticoid receptor antagonist can be administered in a daily amount of about .5  
3 mg to about 35 mg per kilogram of body weight per day.

1                    19.     The kit of claim 17, wherein the instructional material indicates that  
2     the glucocorticoid receptor antagonist can be administered in a daily amount of about 5 to  
3     about 15 mg per kilogram of body weight per day.

1                    20.     The kit of claim 17, wherein the glucocorticoid receptor antagonist  
2     is mifepristone.

1                    21.     The kit of claim 17, wherein the mifepristone is in a form that  
2     permits dosage by way of an aerosol spray.